MEDBOT-B Shares Surge Over 5% as Global Commercial Installations of Toumai Exceed 200 Units

Stock News06-29

The stock of MEDBOT-B (02252) has risen more than 5%. As of writing, it is up 4.95% to HK$22.88, with a turnover of HK$26.08 million.

The company has announced a significant milestone. Following the achievement of over 300 global commercial orders for its core product, the Toumai endoscopic surgery robot, the system has now been installed at the 200th commercial site worldwide. This latest installation took place at the prestigious Spanish medical institution, HM Hospitales. All 200 installed units have received formal acceptance reports from the end customers.

Market Leadership Position

According to publicly available market statistics, the Toumai robot has achieved the highest number of new global commercial installations among domestic Chinese products so far this year. Globally, it ranks within the top two for this metric.

Significance of the Milestone

The company stated that surpassing these dual milestones in commercial orders and installations signifies the accelerating maturity of Toumai's global clinical ecosystem, real-world application framework, and remote collaboration network.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1170620072?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-29 10:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170620072","market":"nz","top_or_hot":-1,"title":"MEDBOT-B Shares Surge Over 5% as Global Commercial Installations of Toumai Exceed 200 Units","media":"Stock News","content":"<p>The stock of <b>MEDBOT-B</b> (<b>02252</b>) has risen more than 5%. As of writing, it is up 4.95% to HK$22.88, with a turnover of HK$26.08 million.<br><br>\nThe company has announced a significant milestone. Following the achievement of over 300 global commercial orders for its core product, the Toumai endoscopic surgery robot, the system has now been installed at the 200th commercial site worldwide. This latest installation took place at the prestigious Spanish medical institution, HM Hospitales. All 200 installed units have received formal acceptance reports from the end customers.<br><br>\n<b>Market Leadership Position</b><br><br>\nAccording to publicly available market statistics, the Toumai robot has achieved the highest number of new global commercial installations among domestic Chinese products so far this year. Globally, it ranks within the top two for this metric.<br><br>\n<b>Significance of the Milestone</b><br><br>\nThe company stated that surpassing these dual milestones in commercial orders and installations signifies the accelerating maturity of Toumai's global clinical ecosystem, real-world application framework, and remote collaboration network.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MEDBOT-B Shares Surge Over 5% as Global Commercial Installations of Toumai Exceed 200 Units</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMEDBOT-B Shares Surge Over 5% as Global Commercial Installations of Toumai Exceed 200 Units\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-29 10:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>The stock of <b>MEDBOT-B</b> (<b>02252</b>) has risen more than 5%. As of writing, it is up 4.95% to HK$22.88, with a turnover of HK$26.08 million.<br><br>\nThe company has announced a significant milestone. Following the achievement of over 300 global commercial orders for its core product, the Toumai endoscopic surgery robot, the system has now been installed at the 200th commercial site worldwide. This latest installation took place at the prestigious Spanish medical institution, HM Hospitales. All 200 installed units have received formal acceptance reports from the end customers.<br><br>\n<b>Market Leadership Position</b><br><br>\nAccording to publicly available market statistics, the Toumai robot has achieved the highest number of new global commercial installations among domestic Chinese products so far this year. Globally, it ranks within the top two for this metric.<br><br>\n<b>Significance of the Milestone</b><br><br>\nThe company stated that surpassing these dual milestones in commercial orders and installations signifies the accelerating maturity of Toumai's global clinical ecosystem, real-world application framework, and remote collaboration network.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"","article_id":"1170620072","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170620072","pubTimestamp":1782699514,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"The stock of MEDBOT-B (02252) has risen more than 5%. As of writing, it is up 4.95% to HK$22.88, with a turnover of HK$26.08 million. The company has announced a significant milestone. Following the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK1100":"医疗保健设备","BK4585":"ETF&股票定投概念","BK1617":"AI医疗","VXUS":"国际股票ETF-Vanguard","02252":"微创机器人-B"},"translate_title":"图迈全球商业安装量突破200台，MEDBOT-B股价飙升逾5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02252":1,"VXUS":1},"content_text":"The stock of MEDBOT-B (02252) has risen more than 5%. As of writing, it is up 4.95% to HK$22.88, with a turnover of HK$26.08 million.\nThe company has announced a significant milestone. Following the achievement of over 300 global commercial orders for its core product, the Toumai endoscopic surgery robot, the system has now been installed at the 200th commercial site worldwide. This latest installation took place at the prestigious Spanish medical institution, HM Hospitales. All 200 installed units have received formal acceptance reports from the end customers.\nMarket Leadership Position\nAccording to publicly available market statistics, the Toumai robot has achieved the highest number of new global commercial installations among domestic Chinese products so far this year. Globally, it ranks within the top two for this metric.\nSignificance of the Milestone\nThe company stated that surpassing these dual milestones in commercial orders and installations signifies the accelerating maturity of Toumai's global clinical ecosystem, real-world application framework, and remote collaboration network.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.0","shortVersion":"4.45.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1170620072","isCrawlerRequest":true}